Budesonide costs as much as it does in the United States because of a combination of factors that have little to do with the drug itself. The active ingredient is decades old and off-patent, yet the inhaler and specialty oral formulations remain expensive due to how drug pricing, insurance middlemen, and regulatory hurdles interact in the U.S. market. In Europe, the same inhalers sell for as little as 1.5 to 8 percent of their U.S. list price.
The Rebate System That Rewards High Prices
The single biggest reason budesonide stays expensive is the rebate system run by pharmacy benefit managers, or PBMs. These are the middlemen who decide which drugs your insurance plan covers and at what cost-sharing level. PBMs negotiate confidential rebates from brand-name drug manufacturers, and those rebates can be enormous. For inhaled corticosteroid combination products like Symbicort (which contains budesonide), rebates approached 50 to 70 percent of the list price before 2024.
Here’s the counterintuitive part: PBMs often prefer drugs with high sticker prices and high rebates over drugs with lower prices and low rebates, even when the final cost to the insurer is the same. That’s because PBM revenue is frequently tied to the size of the rebates they collect. This creates a perverse incentive to keep list prices inflated. PBMs may even steer patients toward pricier brand-name versions by giving them more favorable copays than generics.
When AstraZeneca dropped Symbicort’s list price by 40 percent in 2024 (from $390 to $234), it disrupted this dynamic. Before the cut, if the average rebate was 60 percent, the net price to insurers was roughly $158. After the price drop, rebates could be no more than about 19 percent to keep net revenue steady. With smaller rebates on the table, PBMs had less financial reason to favor the brand name, and generic uptake increased. That price drop illustrates how the old, higher price was partly sustained by the rebate game rather than by manufacturing costs.
Generic Inhalers Are Unusually Hard to Approve
For a simple pill, proving a generic version works the same as the original is straightforward: you measure how much drug reaches the bloodstream and confirm the numbers match. Inhaled budesonide doesn’t work that way. The drug acts locally in the lungs, not through the bloodstream, so standard blood-level tests don’t capture whether the generic delivers the same dose to the same place.
The FDA has acknowledged this is a unique challenge. Drug concentrations can’t be easily measured in the airways, and there’s no standardized method to test how inhaled particles dissolve in lung tissue. Because of this gap, generic inhaler manufacturers typically need to run expensive clinical trials comparing patient outcomes, not just lab measurements. The complex interaction between the device, the formulation, and how a patient actually inhales adds layers of variability that don’t exist with tablets or capsules.
The FDA has been working on clearer approval pathways that wouldn’t require full clinical endpoint studies, but progress has been slow. Draft guidance documents for budesonide powder and budesonide/formoterol inhalers were published in 2015 and 2016, yet the regulatory landscape remains difficult for generic manufacturers to navigate. Fewer generic competitors means less price competition.
Oral Formulations Face Their Own Issues
Budesonide also comes in oral forms (delayed-release capsules and extended-release tablets) used for inflammatory bowel conditions. These formulations use specialized coatings designed to release the drug at precise points in the digestive tract, which adds manufacturing complexity and limits the number of companies producing them. The 9 mg extended-release tablet, for instance, is placed on Tier 5 (the highest, most expensive specialty tier) in at least one major Medicare Part D formulary, with 40 percent coinsurance and prior authorization required. Even the 3 mg capsule lands on Tier 4, a non-preferred tier where patients face coinsurance up to $250 for a one-month supply.
U.S. Prices vs. the Rest of the World
The price gap between the U.S. and other countries is staggering. Asthma and COPD inhalers sold in Europe cost between 1.5 and 8 percent of their U.S. list prices. That’s not a small discount; it means an inhaler listed at $300 in the U.S. might cost $4.50 to $24 in a European country. The difference comes down to the fact that most other wealthy nations negotiate drug prices at a national level, setting a ceiling on what manufacturers can charge. The U.S. historically has not done this for most medications, leaving prices to be set through the opaque rebate-driven system described above.
AstraZeneca’s key budesonide products, including Pulmicort, have lost patent protection in all major markets. Symbicort’s U.S. patents don’t expire until 2025 to 2029, but the underlying budesonide molecule has been generic for years. In countries with national pricing, that generic availability translates directly into lower costs. In the U.S., it hasn’t had the same effect because of the regulatory and PBM dynamics that blunt generic competition.
Ways to Lower Your Cost
If you’re paying a high price for budesonide, several options can reduce your out-of-pocket spending. Discount platforms like GoodRx and Blink Health let you compare prices across pharmacies and often find significantly lower cash prices than what your insurance copay would be. Mark Cuban’s Cost Plus Drug Company sells generics at a markup over wholesale cost, which can be dramatically cheaper for some medications.
If you’re uninsured or underinsured, patient assistance programs exist through multiple channels. PhRMA’s Medicine Assistance Tool is a search engine that pulls together programs offered by drug manufacturers. NeedyMeds connects patients to both manufacturer programs and independent nonprofit assistance. Prescription Hope offers access to brand-name medications for $60 per month per drug through their advocacy service.
For help with copays specifically, the HealthWell Foundation and Patient Access Network Foundation (PAN) provide financial assistance for out-of-pocket costs, including copays, deductibles, and even transportation to medical appointments. The Dispensary of Hope distributes donated medications at no cost through participating pharmacies and clinics. Ask your prescriber whether a generic budesonide formulation or a therapeutic alternative on a lower insurance tier could work for your condition, since even small formulary shifts can cut your costs substantially.